Eric Rowinsky, M.D. (Chairman of CAB)
Eric K. Rowinsky, MD, is principally focused on the comprehensive development and registration strategies of cancer therapeutics of all types. Dr. Rowinsky obtained his BA degree from New York University and his MD from the Vanderbilt University School of Medicine. Following his residency in internal medicine at the University of California, he completed fellowship training in medical oncology and clinical pharmacology at the Johns Hopkins University School of Medicine. From 1987 to 1996, Dr. Rowinsky served as an Associate Professor of Oncology at the Johns Hopkins University School of Medicine where he performed seminal clinical development and pharmacologic studies on paclitaxel, docetaxel, irinotecan, topotecan, among other agents. From 1996-2004, he served as the Director of Clinical Research and later Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio, where he held the SBC Endowed Chair for Early Drug Development from 1996-2005 and was a lead investigator on early developmental studies of many classes of targeted therapeutics such as erlotinib, gefitinib, panitumumab, temsirolimus, ridaforolimus, trabectedin, and many other agents. He was also Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio from 1996-2006. From 2005-2007, Dr. Rowinsky served as the Chief Medical Officer and Senior Vice President at ImClone Systems, responsible for clinical development and regulatory affairs. From 2007-2009, he was an Executive Vice President of ImClone Systems, which became a wholly-owned subsidiary of Eli Lilly after its acquisition. Dr. Rowinsky and his team at ImClone were responsible for approvals of cetuximab (Erbitux) in various indications, as well as ramucirumab in four indications and necitumumbab in one indication. Dr. Rowinsky was the Head of Research and Development, Executive Vice President, and Chief Medical Officer at Stemline Therapeutics from 2012-2015. He is also an Adjuvant Professor of Medicine at New York University School of Medicine. Prior to joining ImClone in 2005, Dr. Rowinsky was a longstanding NCI principal investigator on anticancer drug development grants and integrally involved in pivotal clinical and preclinical investigations which lead to the development of both classical chemotherapeutics and targeted therapies, including a wide variety of cytotoxic and targeted anticancer therapeutics. Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an Associate Editor and Editorial Board Member of Cancer Research (Associate Editor and Reviews Editor), Clinical Cancer Research, Annals of Oncology, Cancer Biology and Therapy and several other oncology journals and has published approximately 310 manuscripts in both the preclinical and clinical research fields. He has also served on the Board of Directors, Scientific Advisory Board and Project Advisory Boards of a large number of pharmaceutical and biotechnology companies and has advised and/or presented aspects of New Drug Applications to the FDA on several occasions. Dr. Rowinsky’s honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. He has also served on the Board of Scientific Counselors of the NCI. Dr. Rowinsky is on the board of directors of several public companies, including Biogen Idec Inc., Navidea Inc., Bind Therapeutics, and Fortress Biotech Inc.
Richard Carvajal, M.D.
Dr. Carvajal is an oncologist/hematologist at Columbia University. He was previously a medical oncologist at the Memorial Sloan Kettering Cancer Center and an Assistant Professor at Weill Cornell Medical College. Dr. Carvajal has been a Principal Investigator for several important clinical trials of novel melanoma drugs, including cobimetinib, vemurafenib, and imatinib. He received his medical degree from the NYU School of Medicine.
Anthony Johnson, M.D.
Tony is the Head of Early Clinical Development at AstraZeneca. He serves on the Board of Cardioxyl and was previously a Venture Partner at OrbiMed Advisors. He led exploratory clinical development, biomarkers, clinical pharmacology and pharmacometrics at Bristol-Myers Squibb to superior productivity and drove translation to clinical proof of concept successfully as VP of Discovery Medicine at GlaxoSmithKline. He also established the GlaxoWelcome Medicines Research Unit and had an academic appointment at Queensland University (U.Q.) for which he achieved tenure. Tony received his medical training and research doctorate at New South Wales University and his M.P.H. from U.Q.. Tony is also a fellow of the Royal Australasian College of Physicians and is board certified in Internal Medicine, Geriatric Medicine, and Clinical Pharmacology with 18 years of broad clinical experience.
Pamela M. Klein, M.D.
Dr. Klein is a medical oncologist with strong expertise in drug development. She currently serves as an advisor/consultant on strategy and drug development to all stages of biotechnology and pharma companies. She is also an expert advisor to several Venture Capital firms. Most recently, Dr. Klein was CMO for Intellikine, where she built and led the clinical development organization enabling several first-in-man studies. Prior to that, Dr. Klein was VP of Development at Genentech where she led the development of a large portfolio of drugs, including Herceptin, that have changed the way breast cancer is treated. Prior to Genentech, Dr. Klein spent 7 years at the National Cancer Institute (NCI) where she built and developed the NCI-Navy Breast Care Center, serving as Research Director for the Center. Klein earned her medical degree from Stritch School of Medicine, Loyola University and completed her internal medicine residency training at Cedar-Sinai Hospital where she received the Leo Rigler Award for Resident of the Year, and the Ben Newman Award for the Most Humanistic Physician. She did a Medical Oncology Fellowship at the NCI, serving as Chief Fellow from 1995-996, and then went on to complete an advanced research fellowship within the Department of Genetics.
Yelena Janjigian, M.D.
Dr. Yelena Janjigian is a medical oncologist who specializes in the treatment of malignancies of the gastrointestinal tract, particularly esophagus and stomach cancers. Her research focuses on the development of new treatments for patients with esophagus and stomach cancers, and she is particularly interested in finding ways to select the best treatments for persons with cancer based on the molecular characteristics of their tumor specimens. Dr. Janjigian runs clinical and translational studies designed to develop a better understanding of the driving factors in the development of stomach and esophagus cancer to develop better prevention, early diagnosis, staging, and treatment strategies. She is the Principal Investigator of national clinical trials. Her research has been supported by grants from the National Cancer Institute and the American Society of Clinical Oncology. Dr. Janjigian earned her medical degree from the NYU School of Medicine.
Paul Chapman, M.D.
Dr. Chapman is a Medical Oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC), which he joined in 1988. He is physician-scientist and specialist in melanoma metastasis, having participated in and led the early stage clinical development of several approved drugs, including vemurafenib and ipilimumab, and multiple drug therapies currently in development with novel mechanisms of action. Dr. Chapman is Vice Chairman of MSKCC’s Research Council and a Professor of Medicine at Weill Medical College of Cornell University. He was appointed to the melanoma “Dream Team” sponsored by the not-for-profit organizations Stand Up To Cancer and the Melanoma Research Alliance. Dr. Chapman received the Wings of Hope Award from the Melanoma Research Foundation in 2007. He is the author of 95 peer-reviewed publications and has been an editorial board member for the journals Cancer, Journal of Clinical Oncology, Current Cancer Therapy Reviews, and Clinical Cancer Research.